Ovid Therapeutics Inc. earnings releases OVID

Annual Quarterly

Ovid Therapeutics Inc. last reported quarterly results on Nov 12, 2025, for Q3 FY2025 (the quarter ended Sep 30, 2025): revenue of $132,000 (-23.7% year over year). It usually reports 43–70 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 43–70 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
Nov 12, 2025 43 days after quarter end	Q3 FY2025 ended Sep 30, 2025	0 -23.7%	-12 +13.2%	—
May 13, 2025 43 days after quarter end	Q1 FY2025 ended Mar 31, 2025	0 -12.2%	-10 +12.5%	—
Mar 11, 2025 70 days after quarter end	Q4 FY2024 ended Dec 31, 2024	0 -46.5%	-9 +39.6%	—
May 14, 2024 44 days after quarter end	— ended Mar 31, 2024	—	—	—
Mar 8, 2024 68 days after quarter end	— ended Dec 31, 2023	—	—	—
Nov 3, 2023 34 days after quarter end	— ended Sep 30, 2023	—	—	—
Aug 4, 2023 35 days after quarter end	— ended Jun 30, 2023	—	—	—
May 5, 2023 35 days after quarter end	— ended Mar 31, 2023	—	—	—

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: OVID (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: New York, NY
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1636651

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.